Publicaciones en las que colabora con Carmen Suárez Fernández (17)

2022

  1. Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial

    BMC Cardiovascular Disorders, Vol. 22, Núm. 1

2021

  1. Admission hyperglycaemia as a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes status: data from the Spanish SEMI-COVID-19 Registry

    Annals of medicine, Vol. 53, Núm. 1, pp. 103-116

  2. Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation

    BMC Cardiovascular Disorders, Vol. 21, Núm. 1

  3. Frequency, risk factors, and outcomes of hospital readmissions of COVID-19 patients

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Nutritional Risk and Mortality at One Year for Elderly Patients Hospitalized with Nonvalvular Atrial Fibrillation. NONAVASC Registry

    Journal of Nutrition, Health and Aging

2019

  1. Acute kidney injury is linked to higher mortality in elderly hospitalized patients with non-valvular atrial fibrillation

    Aging Clinical and Experimental Research, Vol. 31, Núm. 4, pp. 455-461

2018

  1. Adherence to recommendations of the Therapeutic Positioning Report about treatment with oral anticoagulants in elderly patients with atrial fibrillation. The ESPARTA study

    Medicina Clinica, Vol. 151, Núm. 1, pp. 8-15

  2. Baseline functional status as the strongest predictor of in-hospital mortality in elderly patients with non-valvular atrial fibrillation: Results of the NONAVASC registry

    European Journal of Internal Medicine, Vol. 47, pp. 69-74

  3. Rivaroxaban: searching the integral vascular protection

    Expert Review of Clinical Pharmacology, Vol. 11, Núm. 7, pp. 719-728

  4. Type and doses of oral anticoagulants and adherence to anticoagulant treatment in elderly patients with atrial fibrillation: The ESPARTA study

    Journal of Comparative Effectiveness Research, Vol. 7, Núm. 3, pp. 223-232

2017

  1. Cardiovascular efficacy and safety of bococizumab in high-risk patients

    New England Journal of Medicine, Vol. 376, Núm. 16, pp. 1527-1539

2016

  1. Empagliflozin and progression of kidney disease in type 2 diabetes

    New England Journal of Medicine, Vol. 375, Núm. 4, pp. 323-334

  2. RECALMIN. La atención al paciente en las unidades de Medicina Interna del Sistema Nacional de Salud

    Revista Clinica Espanola, Vol. 216, Núm. 4, pp. 175-182

2015

  1. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes

    New England Journal of Medicine, Vol. 373, Núm. 22, pp. 2117-2128

  2. Tratamiento antitrombótico en el paciente anciano con fibrilación auricular

    Revista Clinica Espanola, Vol. 215, Núm. 3, pp. 171-181

2011

  1. Opinión de los médicos expertos en hipertensión sobre las combinaciones triples en España.: Proyecto SINERGIA

    Hipertensión y riesgo vascular, Vol. 28, Núm. 3, pp. 83-90

2007

  1. Prevalencia de enfermedad arterial periférica estimada mediante el índice tobillo-brazo en pacientes con síndrome metabólico. Estudio MERITO I

    Revista Clinica Espanola, Vol. 207, Núm. 5, pp. 228-233